Hydroxyprogesterone caproate Injection IP

Name : MYTERM-H 500

Packing : 2 ml

Price : Rs. 139

Indication :

Composition: Hydroxyprogesterone caproate inj IP
  • Preterm Labor , Amenorrhea(Primary and Secondary),Advanced adenocarcinoma of the uterine corpus
  • HYDROXYPROGESTERONE CAPROATE POTENT
  • LONG-ACTING
  • PROGESTATIONAL STEROID ESTER HELPS REDUCING THE RISK OF PRETERM BIRTH IN WOMEN WITH A SINGLETON PREGNANCY WHO HAVE A HISTORY OF SIGLETON SPONTANEOUS PRETERM BIRTH TRANSFORMS PROLIFERATIVE ENDOTHELIUM INTO SECRETORY ENDOTHELIUM , INDUCES MAMMARY GLAND DUCT DEVELOPMENT WEEKLY INJECTIONS OF 17-ALPHA-HYDROXPROGESTERONE CAPROATE BEGINNING AT 16-20 WEEKS GESTATION RESULTED IN A SUBSTANTIAL REDUCTION IN THE RATE OF SPONTANEOUS RECURRENT PRETERM BIRTH . LONG-TERM FOLLOW-UP OF CHILDREN EXPOSED IN-UTERO TO THE DRUG HAS SHOWN NORMAL GROWTH AND DEVELOPMENT AND NORMAL SCORES FOR GENDER SPECIFIC ROLES . IN CONCLUSION , 17-ALPHA-HYDROXYPROGESTERONE CAPROATE IS CURRENTLY THE ONLY DRUG WITH SUFFICIENT TO SUPPORT ITS USE FOR PREVENTION OF SPONTANEOUS RECURRENT PRETERM BIRTH . IDEAL IN
  • IN PREGNANT WOMEN PRETERM LABOR
  • IN NON-PREGNANT WOMEN FOR THE TREATMENT OF ADVANCED ADENOCARCINOMA OF THE UTERINE CORPUS IN THE MANAGEMENT OF AMENORRHEA ( PRIMARY AND SECONDARY ) IN THE MANAGEMENT OF ABNORMAL UTERINE BLEEDING DUE TO HORMONAL IMBALANCE IN THE ABSENCE OF ORGANIC PATHOLOGY, SUCH AS SUBMUCOUS FIBROIDS OR UTERINE CANCER
Quick Enquiry

whatsapp

Inquire Us

Place a query